Abstracts Archive - Page 830 of 2607 - ACR Meeting Abstracts

Abstract Number: 1873 • ACR Convergence 2021
The Importance of Lower Extremity Vein Wall Thickness in Patients with Behcet’s Syndrome
Hasan Emre Kocabay¹, M. Enes Yayla², Evren Ustuner¹, Emine Uslu yurteri³, Emine Aydemir Guloksuz⁴, Serdar Sezer², Kinikli Gulay⁴, Murat Turgay⁴ and Askin Ates⁴, ¹Ankara University, Ankara, Turkey, ²Ankara Training and Research Hospital, Ankara, Turkey, ³Hatay Training and Research Hospital, Hatay, Turkey, ⁴Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
Background/Purpose: Behçet’s syndrome (BS) is a multisystemic chronic vasculitic disease that has mucocutaneous and joint involvement in addition to vascular, neurological and gastrointestinal involvement (1).…
Abstract Number: 1874 • ACR Convergence 2021
Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis
Kaitlin Quinn¹, Hugh Alessi², Emily Rose³, Mark A. Ahlman⁴, Christopher Redmond⁴, Yiming Luo⁴, Ertugrul Cagri bolek⁵, Carol Langford⁶, Cristina Ponte⁷, Peter Merkel⁸ and Peter Grayson⁹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, Maryland, ³Case Western, Cleveland Heights, OH, ⁴National Institutes of Health, Bethesda, MD, ⁵Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷Hospital de Santa Maria, Lisbon, Portugal, ⁸University of Pennsylvania, Philadelphia, PA, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Disease activity assessment can be challenging in Takayasu’s arteritis (TAK), which can lead to difficulty in determining eligibility for enrollment into randomized clinical trials…
Abstract Number: 1875 • ACR Convergence 2021
Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole
Manuela Osorio¹, Tulio Lopera¹, Teresita Coneo², Isabel Velásquez-Giraldo², Ruben Vargas², Adriana Lucía Vanegas-García³, Mauricio Rojas², Gloria Vasquez⁴ and Carlos Muñoz-Vahos⁵, ¹Universidad de Antioquia, Medellin, Colombia, ²Universidad de Antioquia, Medellín, Colombia, ³Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia, ⁴Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, ⁵Hospital San Vicente Fundación, Medellín, Colombia
Background/Purpose: The Vasculopathy induced by Cocaine-Levamisole (VICOL) is a recently described vasculopathy characterized by the presence of tissue necrosis. One of the possible mechanisms associated…
Abstract Number: 1876 • ACR Convergence 2021
A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome
Yiming Luo¹, Ertugrul Bolek¹, Kaitlin Quinn², Kristina Wells³, Emily Rose⁴, Emily Rominger¹, Levent Kilic⁵, Omer Karadag⁶, Cindy Clark¹, Alicia Livinski¹, Peter Grayson⁷ and Marcela Ferrada¹, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Case Western, Cleveland Heights, OH, ⁵Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁶Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ⁷National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is a rare and poorly understood entity with clinical features of both relapsing polychondritis (RP)…
Abstract Number: 1877 • ACR Convergence 2021
Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics
Yiming Luo¹, Kaitlin Quinn², Marcela Ferrada¹, Elaine Novakovich¹ and Peter Grayson³, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Takayasu’s arteritis (TAK) is an idiopathic inflammatory disease primarily affecting the aorta and its major branches. Mycobacterium tuberculosis is prevalent in developing countries and…
Abstract Number: 1878 • ACR Convergence 2021
Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Diana Prieto-Peña¹, Pilar Bernabeu², Paloma Vela³, Javier Narvaez⁴, Jesús Carlos Fernández-López⁵, Mercedes Freire⁶, Beatriz González-Alvarez⁷, Roser Solans-Laqué⁸, José Luis Callejas⁹, Norberto Ortego¹⁰, Carlos Fernández-Díaz¹¹, Esteban Rubio Romero¹², Salvador Garcia-Morillo¹³, Mauricio Minguez¹⁴, Cristina Carballido¹⁴, Eugenio De Miguel¹⁵, Sheila Melchor¹⁶, Eva Salgado¹⁷, Beatriz Bravo¹⁸, Susana Romero-Yuste¹⁹, Juan Salvatierra²⁰, Cristina Hidalgo²¹, Sara Manrique Arija²², Carlos Romero Gomez²³, Patricia Moya²⁴, Noelia Álvarez-Rivas²⁵, Javier Mendizábal-Mateos²⁶, Francisco Ortiz-Sanjuán²⁷, Ivan Perez De Pedro²⁸, Jose L Alonso-Valdivielso²⁹, Laura Perez-Sanchez³⁰, Rosa Roldan³¹, Nagore Fernandez-Llanio³², Ricardo Gómez de la Torre³³, Silvia Suarez³³, Mara Jess Montesa Cabrera³⁴, MONICA DELGADO SANCHEZ³⁵, Javier Loricera¹, Belén Atienza-Mateo³⁶, Miguel Ángel gonzalez-Gay³⁷ and Ricardo Blanco³⁸, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ³Hospital General Universitario de Alicante, Alicante, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ⁶Rheumatology Service. CHU Coruña, La Coruña, Spain, ⁷H. NªSª de la Candelaria, Tenerife, Spain, ⁸Hospital Vall d'Hebron, Barcelona, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Medicine Department, Universidad de Granada, Granada, Spain, ¹¹Hospital Universitario Reina Sofía, Murcia, Spain, ¹²HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, Seville, Spain, ¹³H Virgen del Rocio, Sevilla, Spain, ¹⁴H. San Juan, Alicante, Spain, ¹⁵Hospital Universitario La Paz, Madrid, Spain, ¹⁶H. 12 de Octubre, Madrid, Spain, ¹⁷Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ²⁰H San Juan, Alicante, Spain, ²¹Hospital Universitario Salamanca, Salamanca, Spain, ²²Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ²³H. Regional de Malaga, Malaga, Spain, ²⁴Hospital Sant Pau, Barcelona, Spain, ²⁵Hospital San Agustín, Aviles, Spain, ²⁶H. Navarra, Navarra, Spain, ²⁷H. La Fe, Valencia, Spain, ²⁸H. Carlos Haya, Malaga, Spain, ²⁹H. Burgos, Burgos, Spain, ³⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³¹H. Reina Sofia, Cordoba, Spain, ³²H. Arnau de Vilanova, Valencia, Spain, ³³H. Asturias, Oviedo, Spain, ³⁴Hospital Universitario Nuestra Seora de la Candelaria, Santa Cruz de Tenerife, Spain, ³⁵H NªSª Candelaria, Tenerife, Spain, ³⁶Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients.…
Abstract Number: 1879 • ACR Convergence 2021
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Elisheva Pokroy-Shapira¹, Iftach Sagy², Katya Meridor³ and Yair Molad⁴, ¹Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, Israel, ²Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ³Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ⁴Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel
Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
Abstract Number: 1880 • ACR Convergence 2021
Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Young³, Cristina Burroughs⁴ and Peter Merkel⁵, ¹Vanderbilt University Medical Center, Franklin, TN, ²University of California Los Angeles, West Hills, CA, ³Vasculitis Foundation, Kansas City, MO, ⁴Health Informatics Institute, Tampa, FL, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Polyarteritis nodosa (PAN) is form of medium-vessel vasculitis with an estimated annual incidence of 1 per million. The rarity of the disease makes traditional…
Abstract Number: 1881 • ACR Convergence 2021
Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease
Youjin Jung and Eun bong Lee, Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Behcet's disease (BD) is characterized by hyper-inflammatory response to trauma, which is called the pathergy phenomenon. Therefore, there are concerns about post-operative complications when…
Abstract Number: 1882 • ACR Convergence 2021
Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
Tannaz Kermani¹, Jason Springer², Dianne Shaw³, Kalen Young⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹University of California Los Angeles, Los Angeles, CA, ²Vanderbilt University Medical Center, Franklin, TN, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Health Informatics Institute, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: To compare the clinical characteristics and determine the reliability of a self-reported diagnosis of giant cell arteritis (GCA) or Takayasu’s arteritis (TAK) from an…
Abstract Number: 1883 • ACR Convergence 2021
Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission
Pablo Vinicius da Fonseca, Henrique Ayres Mayrink Giardini,, Célio Roberto Gonçalves and Leandro Lara do Prado, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis. Neurological involvement, also known as Neuro-Behçet's disease (NBD), leads to great morbimortality. Diagnosis is challenging, since clinical…
Abstract Number: 1884 • ACR Convergence 2021
Real-life Data for the Use of Anti-TNF Treatment in DADA2
Omer Karadag¹, Gizem Ayan², Ozge Basaran³, Ertugrul Cagri bolek⁴, Levent Kilic², Yelda Bilginer⁵, Mehmet Alikasifoglu⁶ and Seza Ozen⁷, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University Pediatric Rheumatology, Ankara, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁶Hacettepe University, Department of Medical Genetics, Ankara, Turkey, ⁷Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 enzyme (DADA2) is an autosomal recessive autoinflammatory disorder associated with ADA2 mutations. ADA2 works as a growth factor and…
Abstract Number: 1885 • ACR Convergence 2021
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Alba Herrero-Morant¹, José Luis Martin-Varillas², Vanesa Calvo-Río³, Santos Castañeda⁴, Olga Maíz⁵, Ana Blanco⁶, Julio Sánchez⁷, Norberto Ortego⁸, Enrique Raya⁹, Anahy Maria Brandy-Garcia¹⁰, Alejandro Olive-Marques¹¹, Agueda Prior-Español¹², Clara Moriano¹³, Elvira Díez¹⁴, Rafael Melero¹⁵, Jenaro Enrique Grana Gil¹⁶, Álvaro Seijas-López¹⁷, Ana Urruticoechea-Arana¹⁸, Ángel Ramos-Calvo¹⁹, Concepcion Delgado-Beltran²⁰, Marta Loredo-Martinez²⁰, Eva Salgado²¹, Francisca Sivera²², Ignacio Torre²³, Javier Narvaez²⁴, Jose Luis Andreu²⁵, Olga Martinez²⁶, Ricardo Gómez de la Torre²⁷, Sabela Fernandez-Aguado²⁸, Susana Romero-Yuste²⁹, Gerard Espinosa³⁰, Miguel Ángel gonzalez-Gay³¹ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Hospital Universitario de Donostia, San Sebastián, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Medicine Department, Universidad de Granada, Granada, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Hospital Germans Trias i Pujol, Badalona, Spain, ¹¹Rheumatology Service. Hospital Germans Trias i Pujol, Barcelona, Spain, ¹²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Spain, ¹³Hospital Universitario de León, León, Spain, ¹⁴Hospital de León, León, Spain, ¹⁵Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁶Hospital Universitario de A Coruña, A Corua, Spain, ¹⁷Hospital Universitario de A Coruña, A Coruña, Spain, ¹⁸H. Can Misses, Elvissa, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰Hospital Clínico Lozano Blesa, Zaragoza, Spain, ²¹Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²²Hospital Universitario de Elda, Alicante, Spain, ²³Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶H. Salamanca, Zamora, Spain, ²⁷H. Asturias, Oviedo, Spain, ²⁸Hospital Universitario de Cabueñes, Gijón, Spain, ²⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Neurobehçet’s disease (NBD) is a severe complication of Behcet's disease (BD). Despite well-established therapies, with glucocorticoids and conventional immunosuppressants (cIS) a significant proportion of…
Abstract Number: 1886 • ACR Convergence 2021
Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis
K. Bates Gribbons¹, SEMA KAYMAZ-TAHRA², Fatma Alibaz³, Ertugrul Cagri bolek⁴, Omer Karadag⁵, Burak Ince⁶, Murat Inanc⁷, Sinem Kocaer⁸, Fatos Onen⁹, KENAN AKSU¹⁰, Gokhan Keser¹¹, Askin Ates¹², Ayten Yazici¹³, Ayse Cefle¹³, Nilufer Alpay Kanitez¹⁴, Ahmet Omma¹⁵, Onay Gercik¹⁶, Servet Akar¹⁷, Veli Cobankara¹⁸, Nazife Sule Yasar Bilge¹⁹, Timucin Kasifoglu²⁰, Mete Kara¹¹, Kaitlin Quinn²¹, Peter Grayson²², Peter Merkel²³ and Haner Direskeneli²⁴, ¹McGovern Medical School, Colleyville, TX, ²Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ⁸Dokuz Eylul University, Izmer, Turkey, ⁹Dokuz Eylul University, Izmir, Turkey, ¹⁰EGE UNIV. FACULTY of MEDICINE, IZMIR, Turkey, ¹¹Ege University, İzmir, Turkey, ¹²Ankara University, Ankara, Turkey, ¹³Kocaeli University, Kocaeli, Turkey, ¹⁴Koc University School of Medicine, Istanbul, Turkey, ¹⁵Ankara City Hospital, Istanbul, Turkey, ¹⁶Izmir Katip Celebi University, Izmir, Turkey, ¹⁷Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹⁸Pamukkale University, Denizli, Turkey, ¹⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ²⁰Osmangazi University Department of Rheumatology, Eskişehir, Turkey, ²¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Marmara University, Istanbul, Turkey
Background/Purpose: Previous studies using computer-driven methods have identified subsets of patients with Takayasu’s arteritis based on angiographic patterns of disease. These subsets were consistent between…
Abstract Number: 1887 • ACR Convergence 2021
Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
Maria Caterina Lagdameo¹, Hyungrok Do² and Johannes Nowatzky¹, ¹Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Population Health, NYU School of Medicine, New York
Background/Purpose: Most current Behçet’s disease (BD) activity assessment tools are strongly based on patient-reported symptoms and findings allowing a wide range of observer-dependent interpretations and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].